Related Experiment Video

Updated: Jan 13, 2026

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse
06:39

An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse

Published on: September 12, 2018

28.4K

Soluble neprilysin and the translational continuum in cardio-oncology

Massimiliano Camilli1,2, Antonio Abbate3

  • 1Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy. massimiliano.camilli91@gmail.com.

Cardio-Oncology (London, England)
|January 8, 2026
PubMed

Insights

Angiotensin-receptor/neprilysin inhibitors (ARNI) show promise for heart failure but not yet in cancer patients. Soluble neprilysin (sNEP) may predict ARNI benefit in chemotherapy-induced heart damage, suggesting precision medicine approaches.

Area of Science:

  • Cardio-oncology
  • Pharmacology
  • Biomarkers

Background:

  • Cardio-oncology faces challenges in translating mechanistic findings to clinical cardioprotection.
  • Angiotensin-receptor/neprilysin inhibitors (ARNI) benefit heart failure but lack efficacy in cardio-oncology.
  • Bridging preclinical insights to patient care remains a significant hurdle.
Keywords:
Cardio-OncologyResearch perspectivesSacubitril/ValsartanSoluble neprilysinTranslational cardiology

More Related Videos

Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo08:53

Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo

Published on: May 25, 2019

12.3K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915